NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax Presentation at Noble Capital Markets Emerging Growth Equity Conference
TL;DR
GeoVax's CEO presentation at NobleCon21 offers investors early insights into vaccine advancements and oncology therapies for potential market advantage.
GeoVax CEO David Dodd will present a corporate update on December 3, 2025 at 3:00 pm ET in Boca Raton, with webcast availability following the event.
GeoVax's vaccine development for immunocompromised patients and cancer therapies represents progress toward better healthcare outcomes and disease prevention worldwide.
GeoVax is advancing directly to Phase 3 trials for its Mpox vaccine and developing novel oncolytic therapies for head and neck cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs announced that its Chairman & CEO David Dodd will present a corporate update at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference to provide investors with current information about the company's vaccine development programs and cancer immunotherapies.
The presentation is scheduled for December 3, 2025, at 3:00 pm ET at the Florida Atlantic University Executive Education Complex in Boca Raton, Florida.
David Dodd, the Chairman and CEO of GeoVax Labs, will be presenting the corporate update titled 'GeoVax Corporate Update'.
Interested investors and guests can register using the discount code GOVXNOBLECON at this registration link to attend at a discounted rate.
Yes, a high-definition video webcast will be available the day after the presentation on Noble Capital Markets' conference website at www.nobleconference.com and on Channelchek at www.channelchek.com, where it will be archived for 90 days.
GeoVax's lead clinical programs include GEO-CM04S1, a next-generation COVID-19 vaccine in three Phase 2 trials for immunocompromised patients and as a booster, and Gedeptin®, an oncolytic solid tumor gene-directed therapy that recently completed a Phase 1/2 trial for head and neck cancers.
Registered attendees can participate in one-on-one meetings with senior GeoVax management in addition to attending the corporate presentation.
GeoVax is also developing a vaccine targeting Mpox and smallpox, and based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation without conducting Phase 1 and Phase 2 trials.
For company information, contact info@geovax.com or call 678-384-7220; for media inquiries, contact Jessica Starman at media@geovax.com.
Visit GeoVax's website at www.geovax.com for current status of clinical trials and other company updates.
Curated from NewMediaWire
